KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Arbutus Biopharma (ABUS) FCF Margin: 2011-2025

Historic FCF Margin for Arbutus Biopharma (ABUS) over the last 15 years, with Sep 2025 value amounting to -1,099.62%.

  • Arbutus Biopharma's FCF Margin rose 44900.00% to -1,099.62% in Q3 2025 from the same period last year, while for Sep 2025 it was -310.54%, marking a year-over-year increase of 75625.00%. This contributed to the annual value of -1,053.83% for FY2024, which is 57456.00% down from last year.
  • Latest data reveals that Arbutus Biopharma reported FCF Margin of -1,099.62% as of Q3 2025, which was down 649.82% from -146.65% recorded in Q2 2025.
  • Arbutus Biopharma's FCF Margin's 5-year high stood at 163.29% during Q1 2022, with a 5-year trough of -1,548.62% in Q3 2024.
  • For the 3-year period, Arbutus Biopharma's FCF Margin averaged around -767.67%, with its median value being -759.13% (2025).
  • As far as peak fluctuations go, Arbutus Biopharma's FCF Margin spiked by 101,422bps in 2022, and later tumbled by 108,026bps in 2024.
  • Arbutus Biopharma's FCF Margin (Quarterly) stood at -613.35% in 2021, then surged by 33,915bps to -274.20% in 2022, then crashed by 53,195bps to -806.15% in 2023, then skyrocketed by 14,535bps to -660.80% in 2024, then skyrocketed by 44,900bps to -1,099.62% in 2025.
  • Its FCF Margin stands at -1,099.62% for Q3 2025, versus -146.65% for Q2 2025 and -759.13% for Q1 2025.